Tocagen Presents Data at the American Society of Gene and Cell Therapy 20th Annual Meeting – PR Newswire (press release)

Title: Long-term follow-up data from 126 patients with recurrent high grade glioma from three Phase 1 trials of Toca 511 and Toca FC: Update and justification for a Phase 2/3 trial Presentation Type: Podium Session: Immunotherapy Clinical Trials for Cancer Presenter: Douglas Jolly, Ph.D., executive vice president of research and pharmaceutical development at Tocagen Summary: As previously presented, data from three Phase 1 trials of Toca 511 and Toca FC in 126 patients with recurrent high grade glioma demonstrate potential benefits, including durable objective responses, extended overall survival and a favorable safety profile.

Title: TOCA 511 & 5-FC: Anti-tumor activity, immune memory and prolonged survival even at low infection levels Presentation Type: Poster Session: Cancer-Immunotherapy, Cancer Vaccines I Presenter: Kader Yagiz, Ph.D., research scientist at Tocagen Summary: Data from preclinical models suggest that even a small percentage of Toca 511 infection results in anti-tumor immune activation and a significant increase in survival following 5-FC treatment.

About Tocagen

Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient's immune system against their own cancer. Tocagen is developing its lead investigational product candidate, Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma (HGG), a disease with significant unmet medical need. Toca 511 & Toca FC was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of recurrent HGG. Tocagen has received grant support from leading brain cancer foundations, includingAccelerate Brain Cancer Cure(ABC2),National Brain Tumor Society(NBTS), American Brain Tumor Association (ABTA),Musella FoundationandVoices Against Brain Cancer (VABC).

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tocagen-presents-data-at-the-american-society-of-gene-and-cell-therapy-20th-annual-meeting-300455756.html

SOURCE Tocagen Inc.

http://tocagen.com/

Follow this link:
Tocagen Presents Data at the American Society of Gene and Cell Therapy 20th Annual Meeting - PR Newswire (press release)